| Popis: |
The growing demand for medicinal herbal preparations, the changing requirements of the regulatory system for their effectiveness and safety during the registration procedure pose certain tasks for their study. For the prevention and treatment of various diseases, along with a wide range of synthetic medicines, herbal medicines are used. At the same time, not only medicinal plants and collections are used as herbal medicines, but also various plant extracts, individual biologically active compounds isolated from plants. A preclinical study of reproductive toxicity seems necessary, since it is known that some medicinal plants have a teratogenic effect [1]. The main task of the preclinical study of the effect of potential drugs on the reproductive system is to prove or exclude the possibility of developing a teratogenic effect caused by a new pharmacological agent in an animal experiment. Mandatory testing for reproductive toxicity should be subject to new, original pharmacological agents, as well as well-known drugs recommended for use in long repeated courses, as well as for the treatment of pregnant women and when prescribed during lactation; as preventive agents and contraceptives [2, 3]. Strawberry garden leaf extract dry (strawberry garden extract) is one of the potential substances for obtaining safe medicines for the prevention and treatment of diseases of the urinary tract, as it has diuretic and anti–inflammatory activity [4]. The study of the reproductive toxicity of strawberry garden extract is a mandatory part of the preclinical safety assessment of a new pharmacological substance for obtaining safe medicines with it. In this regard, studies on the reproductive toxicity of strawberry garden leaves of dry extract are relevant in the framework of preclinical studies and substantiation of the use of the substance for the further development of medicines based on it. |
